Treatment

Hepatitis D is treated with medication; however, there is currently no cure that would completely eliminate the virus from the body—neither for the acute nor for the chronic form of the disease.

The goal of treatment is:

• suppressing the replication of the hepatitis D virus (HDV);
• slowing the progression of liver damage;
• reducing the risk of cirrhosis and hepatocellular carcinoma (liver cancer);
• improvement in prognosis and quality of life for the patient.
  

The treatment strategy is determined solely by the doctor after a complete examination.

---

In Ukraine, pegylated interferon alfa was used to treat viral hepatitis D; however, this drug is currently virtually unavailable in Ukraine and cannot be widely used in clinical practice.

This means that the options for specific treatment of hepatitis D in Ukraine are significantly limited, and most patients require:

• regular medical monitoring;
• monitoring of viral activity and liver function;
• timely detection of complications.
  

---

Current treatment options: promising results

Bulevirtide (Hepcludex)

In the European Union and the United States, Bulevirtide (Hepcludex) is used to treat chronic hepatitis D—the first targeted drug specifically developed for the treatment of HDV.

Clinical trial data show that:

• the drug effectively inhibits hepatitis D virus replication;
• a reduction in HDV viral load is observed in a significant proportion of patients;
• Treatment is associated with a slowing of liver disease progression;
• The safety profile is satisfactory, allowing for long-term use.
  

Hepcludex is already demonstrating real clinical results and is considered a major breakthrough in the treatment of hepatitis D, although it is currently not registered or available in Ukraine; however, Ukrainians can access treatment in some European countries. BCD specialists will provide comprehensive information on the process of obtaining Hepcludex in Germany and support you on your path to recovery.

---

Brelovitug (BJT-778): Future Prospects

Another extremely promising area is Brelovitug (BJT-778)—a monoclonal antibody targeting HBsAg that blocks the spread of the hepatitis D virus.

The results of clinical trials are very encouraging:

• the drug demonstrates a significant reduction in HDV activity;
• it has the potential to be used in patients with severe disease;
• has an innovative mechanism of action that opens up new treatment possibilities.
  

Brelovitug received:

• Breakthrough Therapy designation from the FDA;
• PRIME and Orphan designations from the EMA.
  

The drug is currently in clinical trials but is considered one of the most promising candidates for future treatment of hepatitis D.

Although treatment options for hepatitis D in Ukraine are currently limited, recent international developments provide real grounds for optimism. 

---

We are here to help you navigate these steps calmly and clearly—from testing to the next steps.